| scholarly article | Q13442814 |
| P50 | author | Brian K Link | Q61054699 |
| George J Weiner | Q61983045 | ||
| Matthew J. Maurer | Q74084050 | ||
| P2093 | author name string | Stephen M Ansell | |
| Thomas E Witzig | |||
| Carrie A Thompson | |||
| David J Inwards | |||
| Grzegorz S Nowakowski | |||
| Ivana N Micallef | |||
| Luis F Porrata | |||
| Patrick B Johnston | |||
| Thomas M Habermann | |||
| William R Macon | |||
| James R Cerhan | |||
| Herve Ghesquieres | |||
| Pierre Biron | |||
| Catherine Chassagne-Clément | |||
| Catherine Sebban | |||
| Emmanuelle Nicolas-Virelizier | |||
| Marie Peix | |||
| Thérèse Gargi | |||
| P2860 | cites work | Computed Tomography — An Increasing Source of Radiation Exposure | Q22121933 |
| Cancer statistics, 2013 | Q27860762 | ||
| Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). | Q30479763 | ||
| Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? | Q34131221 | ||
| The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma | Q34190099 | ||
| Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. | Q34193968 | ||
| Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors | Q34231093 | ||
| Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas | Q34283822 | ||
| Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma | Q34288599 | ||
| Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma | Q34866311 | ||
| Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. | Q37040596 | ||
| The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk | Q37607027 | ||
| Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. | Q38184954 | ||
| Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma | Q40318856 | ||
| Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies | Q42163806 | ||
| Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. | Q43170097 | ||
| Relapse patterns of localized non-Hodgkin's lymphoma of the head and neck after clinical remission: results of a strict follow-up procedure | Q43877471 | ||
| Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma | Q44391203 | ||
| Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission | Q45244780 | ||
| Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma | Q46094228 | ||
| High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. | Q46305110 | ||
| Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. | Q53083174 | ||
| Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. | Q53120165 | ||
| Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. | Q53540097 | ||
| The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission | Q80027683 | ||
| Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center | Q83397934 | ||
| The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma | Q84734074 | ||
| P433 | issue | 31 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3506-3512 | |
| P577 | publication date | 2014-09-29 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma | |
| P478 | volume | 32 |
| Q35820192 | Ambulatory Medical Assistance--After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy |
| Q89120053 | Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies |
| Q38909384 | Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas |
| Q35700203 | Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study |
| Q50099990 | Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. |
| Q35198335 | Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer |
| Q52691819 | Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. |
| Q37342972 | Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma. |
| Q41354771 | Current imaging follow-up of non-Hodgkin lymphoma exposes patients to significant radiation but does not detect asymptomatic relapses. |
| Q53280595 | Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. |
| Q37589543 | Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful |
| Q52836250 | Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q33851726 | Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. |
| Q37035820 | Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. |
| Q90671031 | End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al |
| Q39036785 | Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma |
| Q38671671 | Evolution of lymphoma staging and response evaluation: current limitations and future directions |
| Q37632114 | FDG-PET imaging in hematological malignancies |
| Q28077086 | Follow-up care for survivors of lymphoma who have received curative-intent treatment |
| Q38797810 | Imaging of primary pediatric lymphoma of bone |
| Q36558651 | Is Radiation Necessary for Treatment of Non-Hodgkin's Lymphoma of Bone? Clinical Results With Contemporary Therapy |
| Q48171760 | Lack of effectiveness of routine clinic and blood test-based follow-up for diffuse large B cell lymphoma |
| Q50000153 | Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. |
| Q92561299 | Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy |
| Q47568589 | Minimal Residual Disease Assessment in Lymphoma: Methods and Applications |
| Q47873950 | Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions |
| Q49361774 | Nachsorge beim diffusen grosszelligen B-Zell-Lymphom – Evidenz und Empfehlung |
| Q26796428 | Next-generation prognostic assessment for diffuse large B-cell lymphoma |
| Q28084956 | Next-generation surveillance strategies for patients with lymphoma |
| Q89933141 | Non-Hodgkin lymphoma |
| Q48105111 | Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study |
| Q38642477 | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study |
| Q41139081 | Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. |
| Q89088220 | Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials |
| Q38480777 | Rethinking clinical response and outcome assessment in a biologic age. |
| Q38516244 | Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. |
| Q90394469 | Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission |
| Q58767936 | Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma |
| Q39142301 | Surveillance Scans in Lymphoma: Friend or Foe? |
| Q38630219 | Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. |
| Q38598014 | The expanding role of primary care in cancer control. |
| Q55024881 | The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL). |
| Q38268544 | The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials |
| Q38729502 | The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential |
| Q91480167 | Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy |
Search more.